Comparing the actions of lanicemine and ketamine in depression: Key role of the anterior cingulate

European Neuropsychopharmacology

Volumn 26, Issue 6, 2016, Pages 994-1003

  Downey, Darragh ^a   Dutta, Arpan ^a   McKie, Shane ^a   Dawson, Gerard R ^b   Dourish, Colin T ^b   Craig, Kevin ^b   Smith, Mark A ^c   McCarthy, Dennis J ^c   Harmer, Catherine J ^d   Goodwin, Guy M ^d   Williams, Steve ^a   Deakin, J F William ^a,e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b P1VITAL   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anterior cingulate; Antidepressant; fMRI; Ketamine; Lanicemine; Major depressive disorder

Indexed keywords

KETAMINE; LANICEMINE; SODIUM CHLORIDE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; PHENETHYLAMINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ANTERIOR CINGULATE; ARTICLE; BOLD SIGNAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TENSION HEADACHE; YOUNG ADULT; ADOLESCENT; AFFECT; CINGULATE GYRUS; CROSSOVER PROCEDURE; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AFFECT; ANTIDEPRESSIVE AGENTS; CROSS-OVER STUDIES; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GYRUS CINGULI; HUMANS; KETAMINE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PHENETHYLAMINES; PSYCHIATRIC STATUS RATING SCALES; PYRIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84964577685     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2016.03.006     Document Type: Article

References (36)

1. Aan het Rot M., Collins K.A., Murrough J.W., Perez A.M., Reich D.L., Charney D.S., Mathew S.J. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry 2010, 67:139-145.
2. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., Kavalali E.T., Monteggia L.M. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
3. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 1961, 4:561-571.
4. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47:351-354.
5. Bremner J.D., Krystal J.H., Putnam F.W., Southwick S.M., Marmar C., Charney D.S., Mazure C.M. Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J. Trauma. Stress 1998, 11:125-136.
6. Carlson P.J., Diazgranados N., Nugent A.C., Ibrahim L., Luckenbaugh D.A., Brutsche N., Herscovitch P., Manji H.K., Zarate C.A., Drevets W.C. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol. Psychiatry 2013, 73:1213-1221.
7. Deakin J.F., Lees J., McKie S., Hallak J.E., Williams S.R., Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch. Gen. Psychiatry 2008, 65:154-164.
8. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., Kammerer W.A., Quezado Z., Luckenbaugh D.A., Salvadore G., Machado-Vieira R., Manji H.K., Zarate C.A. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010, 67:793-802.
9. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders 2002, New York State Psychiatric Institute.
10. Fu C.H., Steiner H., Costafreda S.G. Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol. Dis. 2013, 52:75-83.
11. Kargieman L., Riga M.S., Artigas F., Celada P. Clozapine reverses phencyclidine-induced desynchronization of prefrontal cortex through a 5-HT(1A) receptor-dependent mechanism. Neuropsychopharmacology 2012, 37:723-733.
12. Kiss T., Hoffmann W.E., Scott L., Kawabe T.T., Milici A.J., Nilsen E.A., Hajos M. Role of thalamic projection in NMDA receptor-induced disruption of cortical slow oscillation and short-term plasticity. Front Psychiatry 2011, 2:14.
13. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
14. Luckenbaugh D.A., Niciu M.J., Ionescu D.F., Nolan N.M., Richards E.M., Brutsche N.E., Guevara S., Zarate C.A. Do the dissociative side effects of ketamine mediate its antidepressant effects?. J. Affect. Disord. 2014, 159:56-61.
15. Mathew S.J., Murrough J.W., Aan Het Rot M., Collins K.A., Reich D.L., Charney D.S. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int. J. Neuropsychopharmacol. 2010, 13:71-82.
16. Mayberg H.S., Brannan S.K., Tekell J.L., Silva J.A., Mahurin R.K., McGinnis S., Jerabek P.A. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol. Psychiatry 2000, 48:830-843.
17. Mayberg H.S., Brannan S.K., Mahurin R.K., Jerabek P.A., Brickman J.S., Tekell J.L., Silva J.A., McGinnis S., Glass T.G., Martin C.C., Fox P.T. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997, 8:1057-1061.
18. McKie S., Del-Ben C., Elliott R., Williams S., del Vai N., Anderson I., Deakin J.F. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology 2005, 180:680-686.
19. McKie S., Richardson P., Elliott R., Vollm B.A., Dolan M.C., Williams S.R., Anderson I.M., Deakin J.F. Mirtazapine antagonises the subjective, hormonal and neuronal effects of m-chlorophenylpiperazine (mCPP) infusion: a pharmacological-challenge fMRI (phMRI) study. Neuroimage 2011, 58:497-507.
20. Mealing G.A., Lanthorn T.H., Murray C.L., Small D.L., Morley P. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J. Pharmacol. Exp. Ther. 1999, 288:204-210.
21. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 1997, 17:2921-2927.
22. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
23. Nugent A.C., Diazgranados N., Carlson P.J., Ibrahim L., Luckenbaugh D.A., Brutsche N., Herscovitch P., Drevets W.C., Zarate C.A. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord. 2014, 16:119-128.
24. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52:998-1007.
25. Pizzagalli D.A. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011, 36:183-206.
26. Rajkowska G., Stockmeier C.A. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr. Drug Targets 2013, 14:1225-1236.
27. Roiser J.P., Elliott R., Sahakian B.J. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology 2012, 37:117-136.
28. Salvadore G., Cornwell B.R., Colon-Rosario V., Coppola R., Grillon C., Zarate C.A., Manji H.K. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol. Psychiatry 2009, 65:289-295.
29. Salvadore G., Cornwell B.R., Sambataro F., Latov D., Colon-Rosario V., Carver F., Holroyd T., DiazGranados N., Machado-Vieira R., Grillon C., Drevets W.C., Zarate C.A. Anterior cingulate desynchonization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 2010, 35:1415-1422.
30. Sanacora G., Smith M.A., Pathak S., Su H.L., Boeijinga P.H., McCarthy D.J., Quirk M.C. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol. Psychiatry 2013.
31. Sanacora G., Smith M.A., Pathak S., Su H.L., Boeijinga P.H., McCarthy D.J., Quirk M.C. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol. Psychiatry 2014, 19:978-985.
32. Sanacora, G., Johnson, M., Khan, A., Atkinson, S.D., Riesenberg, R., Schronen, et al., 2014a. Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and a history of inadequate response to antidepressants: primary results from a randomized, placebo-controlled study (PURSUIT), Poster presentation at the 2014 Annual Meeting of the American Society of Clinical Psychopharmacology. 16-19 June 2014. Hollywood, FL, USA (poster session 2, poster #48), p. 133. Abstract available at: 〈〉. http://ascpmeeting.org/wp-content/uploads/2014/06/Poster-Abstracts-FINAL.pdf.
33. Santana N., Troyano-Rodriguez E., Mengod G., Celada P., Artigas F. Activation of thalamocortical networks by the N-methyl-D-aspartate receptor antagonist phencyclidine: reversal by clozapine. Biol. Psychiatry 2011, 69:918-927.
34. Walter M., Henning A., Grimm S., Schulte R.F., Beck J., Dydak U., Schnepf B., Boeker H., Boesiger P., Northoff G. The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch. Gen. Psychiatry 2009, 66:478-486.
35. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomised trial of N-methyl-D-aspartate antagonist in treatment resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.
36. Zarate C.A., Mathews D., Ibrahim L., Chaves J.F., Marquardt C., Ukoh I., Jolkovsky L., Brutsche N.E., Smith M.A., Luckenbaugh D.A. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol. Psychiatry 2013, 74:257-264.